Valeant Pharmaceuticals International, a specialty pharmaceutical company, engages in the development, manufacture, and marketing of a range of pharmaceutical products. It primarily offers specialty pharmaceutical and over-the-counter (OTC) products in the areas of dermatology and neurology therapeutic classes. The company’s products include Efudex/Efudix for the treatment of multiple actinic or solar keratoses and superficial basal cell carcinoma; Acanya and Atralin gels for the treatment of acne vulgaris; Kinerase, a range of OTC and prescription cosmetic products; Nyal, a range of tablets, liquids, and nasal sprays to treat cough, cold, flu, sinus, and hayfever symptoms; and topical OTC products under the tradenames Dermaveen, Dr. LeWinn’s, and Dr. Renaud. It also offers Diastat/Diastat AcuDial, which are gel formulations of diazepam; Cesamet, a synthetic cannabinoid for the management of nausea and vomiting associated with cancer chemotherapy; Mestinon, an orally active cholinesterase inhibitor used in the treatment of myasthenia gravis; Migranal, a nasal spray formulation for the treatment of acute migraine headaches; and Librax, which is used as adjunctive therapy in the treatment of peptic ulcer and irritable bowel syndrome. In addition, the company provides branded generic products in antibiotics, antifungal medications, and diabetic therapies in Europe; and antibacterials, vitamin deficiency, and dermatology in Latin America. Valeant Pharmaceuticals has a license and collaboration agreement with Glaxo Group Limited to develop and commercialize retigabine, a neuronal potassium channel opener for the treatment of adult epilepsy patients with refractory partial onset seizures. It markets its products to physicians, hospitals, pharmacies, and wholesalers through its sales force, as well as through wholesalers primarily in the United States, Mexico, Poland, and Canada. The company was founded in 1960 and is headquartered in Aliso Viejo, California.

Please note!
Collaboration of companies with shared values is main goal of this project.
We will read your message and redirect it to a company's employee whom it can be as useful as possible.
Your company has 5 opportunities per year to get acquainted with other companies. If you want to increase this amount, please contact us
Please note, that according to EBA Code of Conduct it is prohibited to perform on the EBA platform any coordinated actions, which may limit the competition between the EBA Members.
Write us in case of additional questions and suggestions.

Spelling error report

The following text will be sent to our editors: